Jamie Smith
Media Relations
Email: jamie.smith@molnlycke.com
Phone: +46 723 757507
Filippa Stenberg joins Mölnlycke Board of Directors
Gothenburg, Sweden, 4 June 2025.
Mölnlycke is pleased to announce the election of Filippa Stenberg as a deputy board member to its Board of Directors, as of 22 May 2025. Filippa brings over a decade of experience in active ownership with a focus on healthcare investments. She currently serves as a Managing Director of Patricia Industries, part of Investor AB, where she has been instrumental in driving value creation in several globally leading companies.
“We are delighted to welcome Filippa to the Mölnlycke Board,” said Karl-Henrik Sundström, Chairman of the Board. “Her energy, expertise and experience, as well as her strategic vision, will be a tremendous asset to Mölnlycke as we continue to advance our growth journey.”
“I am honoured to join the Mölnlycke Board at such a pivotal time,” added Filippa. “The company has been experiencing strong growth in a healthcare landscape that is continuously evolving. I very much look forward to working with the team to help fulfil the company’s purpose to revolutionise care for people and planet.”
Filippa Stenberg was born in 1985 and is a Swedish citizen. She has been a board member of Swedish Orphan Biovitrum AB since 2021 and recently joined the board of Affibody Medical AB. She has worked as an investment professional at Investor AB since 2012, Chief Strategy Officer at Atlas Antibodies and analyst at Swedbank. She holds an MSc in Business and Economics from the Stockholm School of Economics.
For more information, please contact:
Latest news
Read all news-
Mölnlycke advocates a holistic approach to healthcare sustainability
New white paper calls for integration of environmental, human and economic metrics in sustainability assessments of medical technologies.
-
Mölnlycke Health Care inaugurates new global headquarters at GoCo Health Innovation City
Gothenburg, Sweden. 21 May 2025 – Mölnlycke Health Care, a global leader in MedTech, has officially opened its new global headquarters at GoCo Health Innovation City in Gothenburg, Sweden—a major milestone in its journey to drive sustainable healthcare innovation.
-
Mölnlycke Health Care’s long-term target to reach net zero emissions validated by Science Based Targets initiative
Gothenburg, Sweden. 13 May, 2025. Mölnlycke’s long-term net zero greenhouse gas (GHG) emission reduction targets have been validated by the Science Based Targets initiative (SBTi), following prior validation of the company’s near-term GHG emission reduction targets.
-
Mölnlycke Health Care supports the Wound Care Collaborative Community initiative to improve wound dressing standards
Gothenburg, Sweden. May 02, 2025. The Wound Care Collaborative Community (WCCC) is leading a groundbreaking initiative looking to develop a standardised pre-clinical testing framework for wound dressings.
-
Mölnlycke Health Care publishes Annual report for 2024
Gothenburg, Sweden. 1 April 2025. Today Mölnlycke Health Care has published its Annual report for 2024, including the sustainability report.
-
New study demonstrates the potential benefits of dressing regime improvements in delivering value-based chronic wound care
-
Mölnlycke Health Care expands investment in Tamer Mölnlycke Care joint venture
Mölnlycke Health Care, a world leading MedTech company, has expanded its commitment to operations in the Middle East by extending its stake from 33.3% to 60% to become majority shareholder in Tamer Mölnlycke Care - a joint venture with Tamer Group, the market leader in healthcare distribution in the Kingdom of Saudi Arabia.
-
Mölnlycke Health Care agrees to acquire leading wound cleansing manufacturer to consolidate its position as global leader in wound care
Mölnlycke signed an agreement to acquire P.G.F. Industry Solutions GmbH, the manufacturer of Granudacyn®, a range of solutions for wound cleansing and moisturizing.
-
Mölnlycke signs a EUR 350 million revolving credit facility
On 28 April 2023, Mölnlycke entered into a new EUR 350 million multicurrency revolving credit facility. The facility has a tenor of five years with two one-year extension options and will be used as a backup for general corporate purposes. The facility is a refinancing of the existing and undrawn revolving credit facility signed in 2017.